Mesoblast Limited vs TeraWulf Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while TeraWulf Inc trades at $17.42 (market cap $8.35B). The key difference: TeraWulf Inc is far larger — about 3.8× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | WULF | |
|---|---|---|
Market Cap | $2.21B | $8.35B |
Sector | Technology | Technology |
52-Week High | $20.96 | $28.98 |
52-Week Low | $12.88 | $5.24 |
Enterprise Value | $2.21B | $10.97B |
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →